Benchmark Reiterates Buy on ICU Medical Following Management Meetings

In a report published Monday, Benchmark Company analyst James Terwilliger reiterated a Buy rating and $69.00 price target on ICU Medical (NASDAQ: ICUI).

In the report, Terwilliger noted, “We were recently marketing with a member of the ICU Medical management team, and we remain comfortable with our 2013 revenue and EPS estimates of $335 million and $2.75, respectively. While we remind investors ICUI had a major push-out in Q1:13 from a major customer, we believe it is positioned for an attractive 2H:13 driven by the Oncology business and a return in core business momentum in the Infusion Therapy business.”

ICU Medical closed on Friday at $58.96.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.